MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xjon.2024.06.021

Медицинская библиотека · JTCVS open · 2024

Durable left ventricular assist devices following temporary circulatory support on a microaxial flow pump with and without extracorporeal life support.

Lewin Daniel, Rojas Sebastian V, Billion Michael, Meyer Anna L, Netuka Ivan, Kooij Janajade, Pieri Marina, Loforte Antonio, Szymanski Mariusz K, Moeller Christian H, Akhyari Payam, Jawad Khalil, Krasivskyi Ihor, Schmack Bastian, Färber Gloria, Medina Marta, Haneya Assad, Zimpfer Daniel, Nersesian Gaik, Oezkur Mehmet, Djordjevic Ilija, Saeed Diyar, Stein Julia, Kraaijeveld Adriaan O, Gustafsson Finn, Scandroglio Mara, Meyns Bart, Hofmann Steffen, Belohlavek Jan, Gummert Jan F, Lanmueller Pia, Bernhardt Alexander M, Potapov Evgenij V

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Circulatory support with a catheter-based microaxial flow pump (mAFP) plays a major role in the treatment of severe cardiogenic shock. In most patients who fail to recover while on temporary mechanical circulatory support (tMCS) and who are not eligible for heart transplantation, durable left ventricular assist device (dLVAD) implantation is usually considered a reliable option. This study aimed to describe the outcome of dLVAD therapy following mAFP support and to identify predictors of mortality.

METHODS

This was a retrospective analysis of data from a multicenter registry on patients who underwent dLVAD implantation following tMCS with a mAFP between January 2017 and October 2022 (n = 332) from 19 European centers.

RESULTS

Patients were supported with an Impella 5.5 (n = 92), 5.0 (n = 153) or CP (n = 87) and were transitioned to a HeartWare HVAD (n = 128) or Heartmate 3 (n = 204) during the same period. One hundred and twenty-five patients (39.2%) also required extracorporeal life support before and/or during mAFP therapy. The 30-day and 1-year survival were 87.8% and 71.1%, respectively. The following risk factors for 1-year mortality were identified: age (odds ratio [OR], 1.02), specifically age over 55 years (OR, 1.09), body mass index >30 kg/m2 (OR, 2.2), female sex (OR for male sex, 0.43), elevated total bilirubin (OR, 1.12), and low platelet count (OR, 0.996).

CONCLUSIONS

Based on the identified risk factors, a risk score for estimating 1-year mortality was calculated to optimize patient selection for dLVAD implantation.

Для цитирования: Lewin Daniel, Rojas Sebastian V, Billion Michael, Meyer Anna L, Netuka Ivan, Kooij Janajade, Pieri Marina, Loforte Antonio, Szymanski Mariusz K, Moeller Christian H, Akhyari Payam, Jawad Khalil, Krasivskyi Ihor, Schmack Bastian, Färber Gloria, Medina Marta, Haneya Assad, Zimpfer Daniel, Nersesian Gaik, Oezkur Mehmet, Djordjevic Ilija, Saeed Diyar, Stein Julia, Kraaijeveld Adriaan O, Gustafsson Finn, Scandroglio Mara, Meyns Bart, Hofmann Steffen, Belohlavek Jan, Gummert Jan F, Lanmueller Pia, Bernhardt Alexander M, Potapov Evgenij V. Durable left ventricular assist devices following temporary circulatory support on a microaxial flow pump with and without extracorporeal life support.. JTCVS open. 2024. DOI: 10.1016/j.xjon.2024.06.021.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.